Table 1 Patient’s characteristics.
From: The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics
Vancomycin | Comparator | |||
|---|---|---|---|---|
N | 5449 | 16.5% | 27,548 | 83.5% |
Gender (female) | 2945 | 14.9% | 16,855 | 85.1% |
Age (years) | 50.4 | ± 15.7 | 50.2 | ± 14.9 |
Treatment duration | ||||
≤ 7 days | 4347 | 79.8% | 23,965 | 87.0% |
8–14 days | 871 | 16.0% | 2845 | 10.3% |
≥ 15 days | 231 | 4.2% | 738 | 2.7% |
Infection coded (yes) | 2242 | 41.1% | 2785 | 10.1% |
Surgical procedure (yes) | 1965 | 36.1% | 13,795 | 50.1% |
Cardiovascular | 246 | 4.5% | 696 | 2.5% |
Heart disease | 710 | 13.0% | 2210 | 8.0% |
Diabetes | 1646 | 30.2% | 6567 | 23.8% |
Hyperlipidemia | 2231 | 40.9% | 10,473 | 38.0% |
Hypertension | 2905 | 53.3% | 13,251 | 48.1% |
Cirrhosis | 256 | 4.7% | 1310 | 4.8% |
Atrial fibrillation | 344 | 6.3% | 1241 | 4.5% |
Hypercalemia | 79 | 1.5% | 446 | 1.6% |
Lupus | 155 | 2.8% | 566 | 2.0% |
Myeloma | 26 | 0.5% | 70 | 0.3% |
Nephrolithiasis | 186 | 3.4% | 1051 | 3.8% |
ACEi | 1003 | 18.4% | 4526 | 16.4% |
ARB | 544 | 10.0% | 2660 | 9.7% |
Statin | 1200 | 22.0% | 5499 | 20.0% |
Beta-blocker | 988 | 18.2% | 4304 | 15.6% |
Ca-channel-blocker | 651 | 12.0% | 3004 | 10.9% |
Alpha-blocker | 215 | 3.9% | 894 | 3.2% |
Thiazide | 707 | 13.0% | 3881 | 14.1% |
K+-sparing diuretics | 244 | 4.5% | 1197 | 4.3% |
Loop diuretic | 438 | 8.0% | 1387 | 5.0% |
Niacin | 63 | 1.2% | 214 | 0.8% |
Fibrate | 172 | 3.2% | 809 | 2.9% |
Ezetimibe | 131 | 2.4% | 610 | 2.2% |
OAK | 604 | 11.1% | 2315 | 8.4% |
Aspirin | 51 | 0.9% | 200 | 0.7% |
NSAID | 1511 | 27.7% | 7671 | 27.8% |
